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Abstract 
BACKGROUND: Primary focal hyperhidrosis is caused by excessive secretion by eccrine sweat 
glands, usually at axillae, palms and soles. The underlying mechanism is unclear. Botulinum toxin A is 
a highly efficient treatment for this condition. A subjective self-assessment scale has been shown to be 
a useful tool in assessing the variation in sweat levels before treatment. It has also been shown that 
treatment of hyperhidrosis with botulinum toxin A increases the patients’ quality of life. OBJECTIVES: 
To study the daily variations of sweating in hyperhidrotic individuals and how this affects quality of life 
(QOL) before and after treatment with botulinum toxin A, using a subjective self-assessment scale. 
METHODS: 18 patients with a history of hyperhidrosis (7 axillary, 5 palmar and 6 general) were 
studied. Each participant self-assessed rates of sweating for 7 days on an hourly basis using a 
subjective evaluation scale (SES) ranging from 0 to 10 before, one, three and six months after 
treatment with botulinum toxin A. The patients also recorded one VAS (Visual Analogue Scale) -QOL 
value before and after treatment. RESULTS: Following treatment, VAS-QOL increased in all patients 
(Median value before and after 5 and 9, respectively, p< 0,01), and there was also a reduction in 
sweating after one and three months in all patients (SESbefore = 4.2, SES1 month = 0.8, SES3 months = 0.9, p 
< 0.0001). After six months, the difference was not significant, but the values had not reached the pre-
treatment level. Different patterns of sweating were observed before treatment, and most patients also 
showed the same pattern after treatment, but the values were lower. CONCLUSIONS: Successful 
treatment of hyperhidrosis with botulinum toxin A gives a significant increase in VAS-QOL and 
significantly decreases the sweat levels after one and three months. 
 
 
 
1.0 Objectives 
To study the daily variations of sweating in hyperhidrotic individuals and how this 
affects quality of life before and after treatment with botulinum toxin A, using a 
subjective self-assessment scale. 
  
 
2.0 Background 
2.1 Introduction to hyperhidrosis 
Hyperhidrosis is exessive sweating beyond what is required to return elevated body-
temperature to normal.1 Physiologically, sweating can occur as emotional, gustatory 
and thermoregulatory. In palms, soles and axillae, the thermoregulatory component 
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of the sweating is minimal.  The condition may be primary (essential) or secondary, 
localized to certain skin areas or generalized. 
 
A number of diseases may induce secondary sweating as a result of indirect 
dysregulation of sweat gland function in localized skin area or the whole body skin. 2  
Some of these conditions are mentioned below:
Generalized :  -    drugs (Propranolol, physostigmine, pilocarpine, TCAs) 
- cardiovascular disease (Increased sympathetic activity) 
- respiratory insuffisience 
- infections (Due to fever) 
- malignant diseases (especially at sleep, mechanisms poorly 
understood) 
- endocrine metabolic disease (f.ex. acromegaly, 
thyreotoxicosis,hypoglycemia, Parkinson disease) 
 
Regional :  -    stroke 
- peripheral nerve damage 
- central or peripheral nerve lesion giving localized anhidrosis with 
compensatory sweating (f.ex. spinal cord injury, Ross syndrome) 
 
 
Focal             :  -    Frey’s syndrome (Can sometimes occur after parotidectomi. The  
cause is that the nerves responsible for saliva secretion grow into 
the cut autonomic nerves of the skin. This leads to redness of the 
skin and sweat secretion on the cheek and temporal region (on the 
operated side) when eating.)32 
- gustatory sweating 
- tumour 
- eccrine tumours 
 
 
Primary focal hyperhidrosis is a disorder characterized by exessive, symmetrical 
sweating in the palms, soles and/or axillae or groin, head or face, of no known 
reason3. Armpits are affected in about 50 % of the patients, feet in 29 %, palms in 25 
% and the face in 20%.3 The exessive sweating must be of at least 6 months 
duration, and two or more of the following criteria need to be present:2 
 
- bilateral and symmetrical sweating (Although axillary sweating 
relatively often occurs not to be symmetrical).  
- sweating interferes with daily activities 
- episodes with severe raised sweating at least once a week 
- presentation before 25 years of age 
- heredity (About 50-70% of the patients) 
- no sweat during sleep 
 
There is a clear hereditary component, and in one study, 67% of the patient reported 
that one of their near relatives had the same condition4. Hyperhidrotic individuals do 
not have an increased number of sweat glands, and the glands are also structurally 
normal and of normal size.3  Hyperhidrosis may develop in early childhood (especially 
palmar, solar sweating), but the presentation of symptoms mostly occurs in puberty 
or early twenties . Mean onset for palmar hyperhidrosis is about 13 years and for 
axillary about 19 years. 3 The disorder seems to be equally distributed between the 
sexes, and has a prevalence of about 1 % in the general population. The disorder 
may have a heavy impact on quality of life and may cause marked psychosocial 
problems. Many patients find that the disorder is keeping them from having a normal 
social life, regarding both spare-time activities and work.26   
    
 Excessive palmar sweating 23    Excessive axillary sweatin g 23                                     
                                                              
 
2.2 Sweat gland morphology 5, 28,29,33 
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There are three different types of sweat glands: eccrine, apocrine and apoeccrine. 
The apocrine glands are mainly located to the axillae and urogenital regions and are 
not involved in the pathopysiology of hyperhidrosis. They are important in producing 
body odour in humans, and this activity is stimulated by androgens and circulating 
adrenalin. In addition, the ducts are supplied by an adrenergic sympathetic nerve.  
 
 
 
Histology of apocrine sweat gland from nipple 25 
The development of eccrine sweat glands are visible in human fetuses at around 3 
months of gestation. They are considered mature by 32 weeks, but do not carry out 
their function before birth. The process starts in the skin of the palmar fingers and 
continues in the soles, axillae and other body areas. In fetal life, the density of the 
sweat gland anlagen is about 3000/cm2 in the 24th gestational week, at birth it is 
about half and at 18 months it has been reduced by another two thirds. The adult 
density of about 120/cm2 is not changed further throughout life.   
The main function of eccrine sweat glands is to allow body cooling by evaporation 
and to moisten the skin, especially on palms and soles. Eccrine sweat glands are 
localized all over the skin surface, but not on mucous membranes. The numbers vary 
greatly with site, and the highest numbers are found in palms, soles and axillae. The 
glands consist of a secretory coil in the junction between dermis and the subcutis and 
a duct portion which deliver the sweat directly to the skin surface. 
 
Birgitte Berntsen and Ritika Gupta 2006 4
  
 
Histology of eccrine sweat gland 24 
 
 
2.3 Sweat production 
The secretory coil produces a fluid; the precursor secrete. The main constituents of 
the precursor secrete is Na, Cl, K, urea and lactate. The concentration of the 
constituents is similar to that of plasma, but it does not contain plasma proteins. The 
precursor secretion is modified while flowing trough the duct portion of the gland. This 
modification involves reabsorption of ions, mostly Na and Cl, which creates a 
hypotonic, water-like fluid. The extent of reabsorption depends on the sweat rate: 
 
Low sweat production:  This is the sweat rate at rest and cool temperatures. In this 
situation the precursor fluid passes the duct slowly. This 
gives time for maximum reabsorption of Na+ and Cl- ions. 
In addition, water is reabsorbed osmotically because of 
the reduced osmotic preassure in the fluid. This leads to a 
small amount of sweat reaching the surface of the skin.  
The finished product consists of a lower concentration of 
Na+ and Cl- and a higher concentration of K+, urea and  
    lactate than in the precursor secretion. 
 
High sweat production: This is the sweat rate at excercise and hot temperatures.  
In this situation, large amounts of precursor secretion are 
produced, and passes the duct rapidly. This gives little 
time for reabsorption of Na+ and Cl- and the amount of 
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water reabsorbed osmotically is therfore also reduced. 
Larger amounts of sweat reach the surface of the skin, 
containing Na+ and Cl- concentrations about one half of 
the plasma concentration. Concentrations of the other 
constituents are also elevated; K+ :20 % higher, urea: 50% 
higher, lactate: about four times higher than plasma levels.  
 
 
 
  
All the cells of the secretory coil are attached to the basement membrane, and 
outside this, there are myoepithelial cells that contract when exposed to 
acetylcholine. The eccrine sweat glands are innervated by sypmpathetic nerve fibres, 
and the presynaptic pathway arises from the intermediolateral cell nucleus within the 
spinal cord.  These fibres synapse in the sympathetic ganglion of the sympathetic 
trunk, and the postsynaptic fibres, which are non-myelinated C-fibres, terminate as 
periglandular nerve endings around the sweat glands. Transmission of a nerve 
impulse through this pathway results in the release of achetylcholine at the nerve 
ending, resulting in activation of the sweat glands. Achethylcholine is the main 
transmitter of the periglandular nerves, but in addition, several other substances have 
been detected by immunohistochemistry. Examples are S-100 protein, substance P, 
vasoactive intestinal polypeptide (VIP) and calcitonine gene-related peptide (CGRP). 
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3.0 Treatment options 
3.1. Topical treatment 
This is the least invasive method and it involves application of aluminium salts on the 
affected area. The effect is due to obstruction of the glands, and possibly atrophy of 
the secretory cells1. The effect of the treatment is approximately 48 hours, and 
repeated applications are necessary. The most common side-effects are irritation of 
the skin, localized burning and stinging. 
 
3.2. Oral treatments 
These are anticholinergic drugs, e.g. oxybutynin (Ditropan). They are antagonists to 
muscarinic acetylcholine receptors in sweat glands, and thereby also the sweat gland 
function. The most common side-effects are orthostatic hypotension, nausea, bladder 
muscular disturbances, inhibition of ejaculation, decreased secretion of saliva and 
disturbances in accommodation. 
 
3.3. Iontophoresis 6  
This method may be used for treatment of palmar and/or plantar hyperhidrosis. It is 
non-invasive, cheap, well tolerated and efficient. In this method, electric current helps 
the transport of ions through the skin. In the direct current method of tap water 
iontophoresis, an average current of 15 mA at a voltage of 20-40 V is most frequently 
used. This gives burning and tingling and it is therefore possible to use lower current, 
e.g. a fixed voltage of 16 V, to avoid this.  
 
Method: The device consists of two electrode plates lowered in a bowl of tap water. 
The patient removes all metal items, and bathes hands and/or feet in the bowl. 
Amperage is slowly being increased, until the patient’s threshold for discomfort is 
reached. Amperage maintains just below this. The treatment should be repeated 
initially 3-5 times per week, for about 20 -30 minutes. Effect is seen after 
approximately 10-15 treatments. When sweating is sufficiently reduced, the treatment 
must be maintained after an individual schedule. 
 
Most common side-effects are dysaesthesia and burning, erythema and urticaria, 
electrical stings by abrupt change in voltage. 
Contraindications are pregnancy, pacemakers and metal implants. 
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3.4. Liposuction/curretage7,8 
This is used for treatment of axillary hyperhidrosis.  The major advantage of this 
procedure, over exicisional surgery, is that it gives much less scarring. 
The procedure is done in tumescent anaesthesia. The patient’s arm (s) are abducted 
approximately 90o, the vaults are painted with iodine and dry sprinkled with starch 
powder. The powder turns black from the sweat and gives the surgeon an idea of the 
area to be treated. Two or three incisions sites are made at the anterior and posterior 
axilla border. A cannula is inserted through the incision sites. The other end of the 
cannula is connected to a suction device which collects the aspirate, so it can be sent 
for histological identification. The suction holes in the cannula have sharp edges 
which gives the opportunity for creation of criss-crossed tunnels. In this way, deep 
dermis and upper subcutaneous fat, including eccrine and appocrine glands, can 
synchronously be removed without damaging the underlying tissue. 
Post-operative a compressive dressing is applied to the axilla for 24 hours, and the 
patient is given prophylactic oral antibiotics and analgetics. After 24 hours the patient 
gets compressive garment for 2 weeks and return to their daily activities within a 
week. Possible complications are recurrence of sweating, bleeding, infection, pain 
and haematoma.  
 
 
3.5. Sympathectomy 9 
The sympathectomy is performed at different levels, depending on the localization of 
the hyperhidrosis:
 
- T2 for face/scalp 
- T3 for palmar 
- T4 for axillary 
 
Operative technique: Both sides are never operated at the same time, and all 
procedures are performed under general anaesthesia. Three thoracoscopic ports are 
used, and CO2 is insufflated to aid in exposure of the sympathetic chain. The correct 
level is identified with the help from the relation between the ribs, and ablated with 
the cautery.  The patients are usually discharged home within the day. Most patients 
return to pre-operative activity level in approximately 3 days. 
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Possible complications: - compensatory sweating is reported in as many as 85 % 
      of the patients in some materials
    - pneumothorax (rare) 
    - bleeding (rare) 
    - Horner syndrome10 
    - Arrhythmias (especially bradycardia) 
 
 
 
3.6. Botulinum toxin A 
Botulinum toxin in general11,12,13,14,15,33:  
The toxin is produced by Clostridium botulinum, an anaerobe, gram positive, spore-
forming bacteria. There are 7 different types of botulinum toxins; A, B, C, D, E, F and 
G. A, B, E, and F cause illness in humans. C. botulinum organisms are cathegorized 
as groups I-IV, depending on which toxin(s) they produce. The toxin is elaborated in 
foods, wounds and infant gut. It is neurotoxic, and amongst the most poisonous 
toxins known (low LD50). The spores are very heat-resistant, but the toxin itself is 
heat-labile, and can be destroyed by heating at a temperature of 80-1000C for 5-10 
minutes.  
Botulinum toxin acts in the cell cytosol on selected proteins, but the toxin must enter 
the nerve endings to exert its effect. The toxin is internalized inside endocytic 
vesicles. They are large zinc metalloproteins of ~150000 Da, composed of two parts: 
A 50000 Da piece which is the catalytic subunit, and a 100000 Da piece, containing 
an N-terminal translocation domain (makes it possible for the light chain to cross the 
endosomal membrane) and a C-terminal binding domain (binds the light chain to the 
vesicle membrane). The light chain and the heavy chain are linked with a disulfide 
bridge. If this bridge is broken before the toxin is inside the cell, the light chain cannot 
enter, and it loses its toxicity.  
 
Target proteins of botulinum toxins are the SNARE proteins (soluble n-
ethylmaleimide-sensitive fusion protein accessory protein receptor). They form a 
heterotrimeric coiled-coil SNARE- complex that induces the docking of the 
neurotransmitter-containing vesicle to the cytosolic face of the presynaptic membrane 
and give fusion between the vesicle and membrane.  
There are two types of SNARE proteins: v-SNAREs and t-SNAREs. Vesicles that bud 
off from a membrane carry v-SNAREs. The target membrane contains t-SNAREs. In 
order for the vesicle to dock on the target membrane, the v-SNAREs must bind to the 
t-SNAREs. 
 
 
 
Transport vesicle docking27
 
 
After docking, a complex of membrane-fusion proteins assembles at the docking site 
and catalyses the fusion with the target membrane.  When the SNARE proteins are 
cleaved by botulinum toxin, the SNAREs cannot mediate fusion of the vesicle and the 
target membrane. By all the above mentioned mechanisms, botulinum toxin leads to 
the inibition of the release of acetylcholine at the presynaptic membrane of 
cholinergic nerve terminal. Hence, the nerve impulses cannot be transmitted.   
 
For types B, D, F and G, the target is VAMP/synaptobrevin. VAMP forms a family of 
vesicular SNAREs, and different isoforms (especially VAMP 1 and 2) are located on 
cell vesicles and contribute to guide each vesicle to their target membranes for 
fusion; neuroexocytosis. Types A and E cleave a protein associated with the 
presynaptic membrane; SNAP25 (25 kD synaptosome-associated protein). There are 
few isoformes of SNAP25. They bind to the target membrane via fatty acids, which 
are linked to cysteine residues in the polypeptide chain of the SNAP protein. 
Botulinum toxin C cleaves SNAP25 and syntaxin, another protein involved in 
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neuroexocytosis. Syntaxin binds to the target membranes via a hydrophobic tail. The 
isoforms mainly involved in neuroexocytosis are 1A, 1B and 2. 
 
Botulinum toxin A in the treatment of hyperhidrosis17,18,19,:  
This method is mainly used for the treatment of axillary and palmar hyperhidrosis.  
The procedure is described below (Material and methods). The advantages of this 
method is that it is minimally invasive, extremely efficient without the induction of 
side-effects, which is reported in many studies. The patients report improvement in 
several daily –life activities: Improvement in state of mind, emotional status, social 
situations, work productivity, engage in sex and athletic activities. In one study26 it 
was shown that the quality of life was significantly increased after treatment with 
botulinum toxin A, especially regarding social activities such as being in public places 
and meeting people for the first time. After treatment, the negative consequences on 
the emotional status because of hyperhidrosis, was also reduced. When comparing 
quality of life for patients with hyperhidrosis and patients with other skin diseases, 
such as acne vulgaris and psoriasis, the hyperhidrotic patients have a lower quality of 
life than these groups of patients. This is shown to be improved after treatment with 
botulinum toxin A.30,31 One study also reported reduction in depression, anxiety and 
social phobia.31  It is also a safe treatment that can be repeated without the problem 
with formation of neutralizing antibodies against the toxin.  
Very few side-effects are reported; such as pain during the procedure and dryness of 
the palmar skin requiring moisturiser at times. Slight reduction in power of the thumb-
index finger grip is seen in one study (Swartling et.al)20, and is most pronounced 3 
weeks after the injections. This is most often seen in median innervated muscles, but 
also in muscles with ulnar nerve supply. The methods used to measure effects of 
botulinum toxin in muscles were repetitive nerve stimulation, single fibre EMG, 
measurements of muscle power and compound muscle action potential (CMAP). The 
muscle strength returns to normal after some weeks. In this study 76 % of the 
patients experienced muscle weakness, but 91% still wanted the same dose of Botox 
when having a new treatment, telling us that the effect of Botox treatment is more 
beneficial to the patient than the disadvantage of slightly reduced grip function.  In 
another study (Lowe et. al)21, reduction in grip strength was not seen. In contrast to 
the sympathectomy, compensatory sweating does not prevail after the botulinum 
toxin treatment16. There are some disadvantages with botulinum toxin treatment: It is 
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expensive (2000 NOK for 100 E Botox) and must be repeated. The duration of the 
treatment lasts approximately 4-12 months. 
 
Precautions: Adrenaline, prednisolone and antihistamine should be available in case 
of severe reactions to the drug. Effective and safe use of botulinum toxin is 
accomplished by proper storage (2-8oC refrigeration), correct dose and proper 
administration techniques.33 
 
Drug interactions: One must pay extra attention to drugs that may cause increased 
muscle weakness (aminoglycosides, cyclosporine) or antagonize the onset of 
paralysis from botulinum toxin (aminoquinolines, d-penicillamine, tubocurarine, 
succinylcholine) by either: 
1) Action on the cell membrane by inhibiting the binding of the toxin or preventing 
transport into the cell. 
2) Action in the cell interior which inhibits the lysosomal processing of the toxin.33 
   
Contraindications are infection at the injection sites, neuromuscular disorders (such 
as myasthenia gravis), peripheral motor neuropathic diseases (such as amyotrofic 
lateral sclerosis), pregnancy and lactation, organic causes of hyperhidrosis and 
medications that may interfere with neuromuscular transmission3,33. 
 
4.0 Material and methods 
In this study we included 18 patients; 3 men and 15 women. The patients were 
divided into three groups:  - axillary (total: 7 patients; 1 man, 6 women)  
    - palmar (total: 5 patients; 1 man, 4 women) 
    - general (total: 6 patients; 1 man, 5 women)  
 
The median age in our material was 26,5 (range 14-62). The median age of the 
women was 26 years, and 35 years for the men. Figure 1 below shows the 
distribution within the groups, concidering sex, age and type of hyperhidrosis. 
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Figure 1  Distribution of age, sex and type of hyperhidrosis 
 
 
For the 18 patients as a total, the median age of presentation was 13,5 years. (range 
1-58). However, this variable varies between the groups. Median age of symptom 
appearance for the axillary group (women + man) was 16 years (range 6-30). For the 
palmar group 13 years (range 1-13) and for the general group 14,5 years (range 1-
58) 
It is a well-known phenomenon that hyperhidrosis has a clear hereditary component. 
In our study, 6/7 of the patients in the axillary group, 4/5 in the palmar group and 3/6 
in the general group had one ore more relatives with similar problems.  
In our material, all patients were eihter working (office/sitting job: 6 patients, job 
requiring physical activity: 6 patients) or students (6 patients). 
2 of the axillary patients, 3 in the palmar group and 4 with general hyperhidrosis 
reported that they have and/or have had additional diseases.  These are: 
Endometriosis, hypothyreosis, chronic urinary tract infections, contact dermatitis, 
psoriasis, rheumatoid arthritis, osteoporosis, erythromelalgia, depression, asthma 
and atopical eczema.  
3/18 of the patients were smokers, and 5/18 of the patients reported that they have 
had allergic reactions when exposed to certain allergens. 
 
 The patients were referred for treatment to the regional centre, where the diagnosis 
was confirmed by one dermatologist. The diagnosis criteria was confirmed upon 
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clinical findings, iodine-starch test (in axillary patients) and the interview containing 
the relevant questions regarding the condition connected to2: 
 
 Pattern of sweating (which areas are involved?) 
  - daily variations?  
  - duration 
  - symmetrical sweating? 
  - are there any trigger factors? 
  - age of presentation 
  - does the sweating interfere with daily activities / quality of life? 
  - heredity 
  - check for symptoms that indicate secondary hyperhidrosis 
 
The patients were asked to assess their sweating on a premade diary schedual on an 
hourly basis from 8 am to 12 pm for 7 following days before the treatment. The 
sweating (SES –subjective evaluation sweating score) was evaluated, using a scale 
from 0 to 10, where 0 means “no sweating” and 10 means “the most intense sweating 
the patient can imagine”. They are also encouraged to make free-text comments, 
regarding e.g. physical activity, stress, etc. for each SES to explain the variations in 
levels of sweating during the day and give information about underlying causes that 
give increased sweating22. SES has been demonstrated to be useful when studying 
variations in sweating, and also in the diagnostic process. The patients were also 
asked to fill in a questionnaire regarding several aspects of hyperhidrosis (including 
age at presentation, heredity, smoking and allergy). The questionnaire also  
contained a VAS scale of subjective judgement of quality of life (QOL). The patients 
were asked to assess their quality of life on a scale ranging from 0 -10.  
In addition they were asked to fill in and diaries and assess quality of life 1,3 and 6 
months after the treatment. The treatment is accomplished by the following 
procedure, and differed between the types of hyperhidrosis16: 
 
Palmar: The median and ulnar nerves are anaesthetized, using lidocaine  
10 mg/ml-1, 5 ml for each nerve.  Botulinum toxin A (Botox®, Allergan) 
100 U is dissolved in 1 ml saline. The injection sites, which are 1,5 cm 
apart, are marked with ink before giving Botox.  Each finger is injected 
in 7 sites, 2 in proximal and middle phalangs and 3 in distal phalangs, 
using a 30-µL syringe with a 30 G x 8-mm needle. Each hand is given 
approximately 75-80 injections. The duration of the treatment is 
approximately 90 minutes for both hands. 
 
 Palmar hyperhidrosis before treatment                
 
 
The injection sites marked with ink dots 
 
 
  
 The syringes containing Botox 
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 Injection of Botox in the palm 
 
 
  
 Treated palm (left) and untreated palm (right) 
 
 
 
 
Axillary: The area to be treated is outlined using the iodine-starch test. No  
anaesthesia is given. 50 U of Botox diluted in 4 ml saline was injected 
intracutaneously (30 G needle) with approximately 15-20 in each axilla. 
The duration of the treatment is 5-10 minutes for each axilla. 
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 Iodine-starch test  
 
 Iodine-starch test completed. The black colour outlines the area to be  
 treated 
  
The axilla marked with ink dots23
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General: These patients were treated with an anticholinergic drug; oxybutynin 
(Dridase). The dose used was 5mg x 2. 
 
 
4.1 Statistical analysis 
Analysis of total scores of VAS-QOL and SES-values was performed by a non-
parametric Mann-Whitney-Wilcoxon test for paired samples. When comparing the 
SES-values before and after treatment in the axillary and palmar group only, we used 
Friedman’s test for related samples, since we had several values for each patient. A 
Wilcoxon test was used to compare the two groups when significant calculations 
were achieved with Friedman’s test. Statistical significance was concidered at 
p< 0,05. Non-parametric statistics were used, as a normal distribution could not be 
assumed in the limited number of data sets. 
 
 
5.0 Results 
30 patients were included in the present study. During the post treatment period 12 
dropped out and further analyses are based on 18 patients. 
 
 
5.1. Quality of life 
We have data regarding VAS-QOL from 6 patients in the axillary group, 4 in the 
palmar group and 5 in the group with general hyperhidrosis. We only used the 
information from the patients with registration both before and after treatment. If the 
patients provided information about VAS- QOL at several follow-ups, we used the 
highest value recorded. Irrespective of sweat localization or treatment modality all 
three groups of patients showed an increase of VAS-QOL after the treatment. (Fig. 
2abc below).  
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Fig. 2  Median VAS-QOL before and after treatment of the patients with a) axillary sweating 
(n=6), b) palmary sweating (n=4) and c) general sweating (n=5). The after treatment value 
represent the single highest reported VAS-QOL value for each patient in the follow up period.  
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Median value summarized from the three groups of patients before treatment was 5 
(median, range 0-10). After the treatment, the value increased to 9 (range 5-10, 
p<0,01, n=15). Fig. 3 below. 
Total scores
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Figure 3  Median VAS-QOL, 95 % confidence interval and range before and after treatment in all 
patients (p=0,002, n=15). The after treatment value represent the single highest reported VAS-
QOL value for each patient in the follow up period.  
 
 
5.2 SES-values before and after treatment 
In the whole group of patients we found a clear significant decrease from baseline  
one and three months after the treatment with respectively botulinum toxin and 
peroral medication. (SES = 4.2, n=15 before treatment. One month after treatment 
SES=0.8, n=17, and three months after treatment SES=0.9, n=12. p<0.0001). (Fig. 
4abc). 
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Figure ariations in SES-values during the week before and after treatment. Coloured 
 
 
 
 
 
 
 
 
 
 
 4   V
lines indicate treatment status, see explanatory text in figure; a) Whole group, 
n=18  b) axillary group, n=7  c) palmar group, n=5 
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ean SES-values before the botulinum toxin treatment was 5.5, n=11. A statistical 
0) 
 to 
 
 
 
 
igure. 5  Mean SES-values in the axillary and palmar group of patients. The measurements at 
 
M
significant reduction was found between baseline SES-values and the values 
recorded 1 (SES=0.21, n=12, p=0,006) and 3 months (SES=0.17, n=9, p=0,00
after treatment. Six months after treatment, the SES- value was still reduced near
a significant level (p=0,069, n=7). The SES was quite stable over the week in all 
groups of patients both before and after the treatment.  (Fig.5 below) 
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2 weeks after treatment was only performed by the palmar patients. **p<0,01,***p<0,001 
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.3. Hourly oscillations in SES-values  
ation of oscillations in sweating before and 
xillary group (patients 1-7): 
  
   
5
We have in detail observed the hourly vari
after the treatment. (See fig. 6 a-k) 
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Figure 6 a-k    Patients’ hourly registrations of sweating during one week. 
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.0. Discussion 
istically significant increase in VAS- QOL after the treatment in all 
 
ese 
 
The 
 
hort 
fter treatment we found a significant reduction in sweating after 1 and 3 months in 
 
. In 
 
. 
 
e 
e 
roup of general hyperhidrosis too few patients finished the study and 
al 
 
6
We found a statst
patients. Because of the drop outs it was not possible to make statistical calculations
on each group separately. However, the results show that regardless of the type of 
hyperhidrosis, a reduced sweat level gives an increase in VAS-QOL. We may 
assume that the hyperhidrosis itself is the cause of the reduced VAS-QOL in th
patients. It would, however, be interesting to compare the before levels of VAS-QOL
before treatment with a similar assessment in a group of healty controls to be certain 
that the increase in VAS-QOL is due to the decreased levels of sweating.  
The increase in VAS-QOL is in well accordance with previous studies.26,30  
advantage with this instrument is that it is a very simple method in contrast to the
more complicated questionnaires such as DLQI(Dermatology Life Quality Index), 
HHIQ(Hyperhidrosis Impact Questionnaire and SF-12 (Medical Outcomes Trust S
Form-12 Health Survey).    
 
A
all patients. After 6 months, the difference was not significant, but the values had not
reached the pretreatment level. This is in accordance with previous findings. 
Reduction of sweat after the botulinum toxin treatment last for 3 to 18 months
most studies a medium of 6 month duration has been documented.19,21,32 Patients
with axillary hyperhidrosis follow the same pattern however, their sweat level at 6 
months is still considerable reduced although it did not reach statistical significance
In the palmar group, the level at 6 months is higher than the level before treatment. 
This is interesting, because there is no evidence that treatment with botulinum toxin 
further increases the sweating when the treatment effect is diminished. One possible
explanation may be that psychological factors play an important role: When the 
sweating returns after a period of minimal sweating problems, it might seem mor
excessive than before treatment, since the patients have adapted to a life without th
manifestations of hyperhidrosis and therefore exaggerate the symptoms when they 
return. 
In the g
therefore it is not possible to make conclusions about the efficacy of the peror
treatment. The few patients who finished the whole study had a good effect of the
medication and an increase in VAS-QOL as patients treated with botulinum toxin.  
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he patients were instructed to fill in a SES-value in the diary every hour from 8 a.m. 
shed in the axillary group before treatment: Some 
a 
 patterns: Before treatment, some show 
ter 
s 
e also have to take into consideration, that it is every patient’s own experience of 
 
le 
 
nsitive 
r 
information about the efficacy of treatment. 
T
to midnight, but not all hours were filled in. We interpreted the hours without 
registration as SES-value= 0.  
Two patterns could be distingui
showed large variations in SES-values during the day, while others demonstrated 
stable pattern of high values. One and 3 months after treatment, the patients who 
had great variations prior to treatment also have variations after treatment, but the 
values are lower. The patients that showed a stabile pattern before treatment, also 
show this 1 and 3 months after treatment. 
For the palmar patients, we recognize three
great variation, some have a more stable pattern in the middle of the SES-scale, 
while others have very low values most of the time, but with occasional spikes. Af
one month, SES-values for most patients have fallen to almost zero. After 3 months, 
some of the patients still have full effect of the treatment, and some have regained 
their sweating, but at lower values compared to levels before treatment. The patient
that had low values before treatment reported that they had asessed the SES-values 
during the summer during the vacation, and therefore these values did not 
demonstrate their every day values during the year.  
 
W
sweat intensity and level that makes up the base of our material. Their assessments
varies with physical activity, stress, etc22 and other every day factors. We have not 
recorded this type of information. However, it is probable that the patients keep on 
with the same type of acitivty, work and exposure to stressful events during the who
study period. The subjective experience of, what is “high” level and what is “low “in 
this group of patient varies between the patients. The patients judge the sweating in
a personal manner. However, the judgements seem to be relatively consistent from 
day to day in each subject although a large hourly variation was obtained in many 
patients. SES diary seems to constitute a good way of assessing this dynamic and 
fluctuating symptom in lack of objective methods to continuously measure the 
sweating in the every day life of the patient.  SES is shown to be sufficiently se
to give accurate information about the sweat levels in each patient, and is also a 
unique tool to demonstrate the daily variations of sweating22, both before and afte
treatment. In addition, it is helpful in the diagnostic process and provides useful 
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dy. During follow-ups only 18 completed 
e diaries. This might be due to the fact that the patients improved. SES-levels near 
herefore 
.0. Conclusion 
 this study, we have shown that the patients have a significant increase in VAS-
nt for hyperhidrosis. We can also conclude, that treatment of 
 3 
 
Originally, we included 30 patients in this stu
th
to zero might be boring to register and it is possible that they in such cases 
considered the information less interesting and irrelevant.  It is also a possibility that 
some of the patients did not experience desired effect of the treatment and t
lost the interest for further participation. Some of the patients probably felt that the 
SES-registration was too demanding and took too much time. This explanation 
seems most probable since we have checked the hospital records, and found that 
several of the drop out patients were satisfied, and have returned for further 
treatment. 
 
 
 
7
In
QOL after treatme
hyperhidrosis with botulinum toxin A gives a significant reduction in sweating 1 and
months after treatment.  
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